CoChat

Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?

Open access
Ioannidis, John PA · 2008 · Philosophy, Ethics, and Humanities in Medicine

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Abstract

Antidepressants, in particular newer agents, are among the most widely prescribed medications worldwide with annual sales of billions of dollars. The introduction of these agents in the market has passed through seemingly strict regulatory control. Over a thousand randomized trials have been conducted with antidepressants. Statistically significant benefits have been repeatedly demonstrated and the medical literature is flooded with several hundreds of "positive" trials (both pre-approval and post-approval). However, two recent meta-analyses question this picture. The first meta-analysis used data that were submitted to FDA for the approval of 12 antidepressant drugs. While only half of these trials had formally significant effectiveness, published reports almost ubiquitously claimed significant results. "Negative" trials were either left unpublished or were distorted to present "positive" results. The average benefit of these drugs based on the FDA data was of small magnitude, while the published literature suggested larger benefits. A second meta-analysis using also FDA-submitted data examined the relationship between treatment effect and baseline severity of depression. Drug-placebo differences increased with increasing baseline severity and the difference became large enough to be clinically important only in the very small minority of patient populations with severe major depression. In severe major depression, antidepressants did not become more effective, simply placebo lost effectiveness. These data suggest that antidepressants may be less effective than their wide marketing suggests. Short-term benefits are small and long-term balance of benefits and harms is understudied. I discuss how the use of many small randomized trials with clinically non-relevant outcomes, improper interpretation of statistical significance, manipulated study design, biased selection of study populations, short follow-up, and selective and distorted reporting of results has built and nourished a seemingly evidence-based myth on antidepressant effectiveness and how higher evidence standards, with very large long-term trials and careful prospective meta-analyses of individual-level data may reach closer to the truth and clinically useful evidence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1747-5341-3-14

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Anticipated mean and range of average effect size (ES) for trials in countries where a drug is approved, when the true average effectiveness is ES = 0.20 and the standard deviation (SD) of the estimated ES across trials is 0.20, 0.40, and 0.60. Trials are assumed to be of similar size and similar weight in the calculations. Forty approval packages with 5 trials each have been simulated in each of the three settings and the data show the ES in the successful packages (those where the average ES is at least 0.20).
Figure 1 Anticipated mean and range of average effect size (ES) for trials in countries where a drug is approved, when the true average effectiveness is ES = 0.20 and the standard deviation (SD) of the estimated ES across trials is 0.20, 0.40, and 0.60. Trials are assumed to be of similar size and similar weight in the calculations. Forty approval packages with 5 trials each have been simulated in each of the three settings and the data show the ES in the successful packages (those where the average ES is at least 0.20).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 288

Metadata

Authors
Ioannidis, J. P.
Affiliations
University of Ioannina (GR)
Corresponding author
Ioannidis, John PA
Venue
Philosophy, Ethics, and Humanities in Medicine
Published
2008
Volume
3
Issue
1
Pages
14
ISSN
1747-5341 (ISSN-L)
OpenAlex
W2026828867
Cited by
253
References
49
Citations by year
2026: 2 · 2025: 9 · 2024: 9 · 2023: 18 · 2022: 19 · 2021: 5 · 2020: 41 · 2019: 15 · 2018: 16 · 2017: 7 · 2016: 9 · 2015: 11 · 2014: 12 · 2013: 14 · 2012: 29
FWCI
8.40
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Philosophy Ethics and Humanities in Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
Keywords
antidepressants, evidence-based medicine, publication bias, selective reporting, FDA drug approval, baseline depression severity, placebo response, major depressive disorder, statistical significance, pharmaceutical industry
MeSH terms
Antidepressive Agents, Major Depressive Disorder, Drug Industry, Humans, United States, United States Food and Drug Administration, Meta-Analysis as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Drug Approval, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? https://app.cochat.ai/papers/10.1186/1747-5341-3-14
The paper
Ioannidis, J. P. (2008). Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philosophy, Ethics, and Humanities in Medicine. https://doi.org/10.1186/1747-5341-3-14

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.